OncoMatch/Clinical Trials/NCT07291076
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Is NCT07291076 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Pumitamig and Ipilimumab for hepatocellular carcinoma (hcc).
Treatment: Pumitamig · Ipilimumab · Atezolizumab · Bevacizumab — The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Local Institution - 0070 · Los Angeles, California
- Local Institution - 0107 · Chicago, Illinois
- John Theurer Cancer Center at Hackensack University Medical Center · Hackensack, New Jersey
- Local Institution - 0100 · Great Neck, New York
- Local Institution - 0080 · Portland, Oregon
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07291076 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages